We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+302.07%
AUM
$47.8B
AUM Growth
+$3.07B
(+6.9%)
Cap. Flow
-$507M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
17.74%
Holding
1,131
New
130
Increased
292
Reduced
306
Closed
143
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$526M |
| 2 |
Ally Financial
ALLY
|
+$198M |
| 3 |
CSX Corp
CSX
|
+$191M |
| 4 |
NetEase
NTES
|
+$173M |
| 5 |
Norwegian Cruise Line
NCLH
|
+$171M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$262M |
| 2 |
CVS Health
CVS
|
+$240M |
| 3 |
Mastercard
MA
|
+$204M |
| 4 |
McKesson
MCK
|
+$201M |
| 5 |
Molson Coors Class B
TAP
|
+$171M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.83% |
| 2 | Communication Services | 13.94% |
| 3 | Technology | 12.15% |
| 4 | Financials | 10.5% |
| 5 | Energy | 9.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Xerox
XRX
$337M
| $290M | 0.61% |
8,844,306
+3,560,343
| +67% | +$113M |
|
52
Hartford Financial Services
HIG
$38.5B
| $268M | 0.56% |
7,489,026
-756,241
| -9% | -$26.6M |
|
53
CNX Resources
CNX
$4.85B
| $268M | 0.56% |
6,975,179
-3,233,043
| -32% | -$118M |
|
54
Comcast
CMCSA
$79.1B
| $267M | 0.56% |
9,937,858
-426,662
| -4% | -$11M |
|
55
Regions Financial
RF
$26.3B
| $265M | 0.55% |
24,928,359
+1,700,757
| +7% | +$17.7M |
|
56
Bristol-Myers Squibb
BMY
$127B
| $262M | 0.55% |
5,398,743
+25,837
| +0.5% | +$1.27M |
|
|
CMCSK
57
DELISTED
COMCAST CORP SPL A (NEW)
CMCSK
| $249M | 0.52% |
4,675,699
-94,709
| -2% | -$5.05M |
|
58
Vertex Pharmaceuticals
VRTX
$121B
| $249M | 0.52% |
2,627,189
-129,546
| -5% | -$9.08M |
|
|
TYC
59
DELISTED
TYCO INTL PLC COM SHS (IRL)
TYC
| $247M | 0.52% |
5,181,589
-3,612,049
| -41% | -$163M |
|
60
Intel
INTC
$466B
| $241M | 0.5% |
7,786,465
-2,217,241
| -22% | -$60.8M |
|
|
APC
61
DELISTED
Anadarko Petroleum
APC
| $231M | 0.48% |
2,113,224
-146,679
| -6% | -$14.9M |
|
62
Union Pacific
UNP
$183B
| $231M | 0.48% |
2,311,419
+16,009
| +0.7% | +$1.55M |
|
63
Macy's
M
$6.15B
| $228M | 0.48% |
3,926,354
-101,173
| -3% | -$5.87M |
|
64
IQVIA
IQV
$34.7B
| $227M | 0.47% |
4,261,596
-257,851
| -6% | -$13M |
|
65
Merck
MRK
$324B
| $218M | 0.45% |
3,941,127
-184,176
| -4% | -$10M |
|
66
Qualcomm
QCOM
$176B
| $217M | 0.45% |
2,736,367
-778,368
| -22% | -$61.9M |
|
|
MJN
67
DELISTED
Mead Johnson Nutrition Company
MJN
| $216M | 0.45% |
2,322,850
-136,290
| -6% | -$11.9M |
|
68
Morgan Stanley
MS
$337B
| $214M | 0.45% |
6,605,908
+1,125,471
| +21% | +$34.7M |
|
69
IBM
IBM
$202B
| $210M | 0.44% |
1,212,800
-102,881
| -8% | -$18.5M |
|
70
HDFC Bank
HDB
$119B
| $207M | 0.43% |
17,649,352
-419,564
| -2% | -$4.6M |
|
|
SCHW
71
Charles Schwab
SCHW
$177B
| $204M | 0.43% |
7,575,995
-405,336
| -5% | -$10.6M |
|
|
SWN
72
DELISTED
Southwestern Energy Company
SWN
| $201M | 0.42% |
4,408,585
-265,280
| -6% | -$12.3M |
|
|
SE
73
DELISTED
Spectra Energy Corp Wi
SE
| $199M | 0.42% |
4,696,311
-263,900
| -5% | -$10.6M |
|
74
Exelon
EXC
$48.6B
| $196M | 0.41% |
7,536,047
-372,303
| -5% | -$9.49M |
|
|
75
Ally Financial
ALLY
$13.1B
| $195M | 0.41% |
+8,153,883
| New | +$198M |
|
Similar funds
QCM
Lazard Asset Management's Q2 2014 Portfolio in Review
As of Q2 2014, Lazard Asset Management held 1,131 positions worth $47.8B, up 6.9% from $44.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Lazard Asset Management's Q2 2014 filing shows 130 new, 292 increased, 306 reduced and 143 closed positions. Its largest new stake was Ally Financial: 8,153,883 shares worth $195M. The largest sale was Gilead Sciences, an estimated $262M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 16% a quarter earlier, followed by Communication Services and Technology.
- Lazard Asset Management's largest Q2 2014 buy was Ally Financial: 8,153,883 shares worth $195M.
- Lazard Asset Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $526M increase.
- Lazard Asset Management's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $262M.
- Lazard Asset Management fully exited Mastercard in Q2 2014, selling an estimated $204M.
- Lazard Asset Management's ten largest holdings make up 18% of its $47.8B portfolio in Q2 2014.
- Lazard Asset Management opened 130 new positions and closed 143 in Q2 2014.
- Lazard Asset Management's portfolio value rose 6.9% quarter-over-quarter to $47.8B.
Based on Lazard Asset Management's 13F filing for Q2 2014, filed 12 Aug 2014.